

# Thorsten Schlomm

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2182737/thorsten-schlomm-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

221  
papers

10,140  
citations

48  
h-index

95  
g-index

242  
ext. papers

11,920  
ext. citations

6.3  
avg, IF

5.32  
L-index

#	Paper	IF	Citations
221	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , <b>2015</b> , 163, 1011-25	56.2	1713
220	Circulating miRNAs are correlated with tumor progression in prostate cancer. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 608-16	7.5	448
219	MicroRNA in prostate, bladder, and kidney cancer: a systematic review. <i>European Urology</i> , <b>2011</b> , 59, 671-80	8.2	355
218	Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. <i>Cancer Cell</i> , <b>2013</b> , 23, 159-70	24.3	259
217	Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. <i>American Journal of Pathology</i> , <b>2012</b> , 181, 401-12	5.8	256
216	ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5878-88	12.9	225
215	Quantitative comparison of DNA methylation assays for biomarker development and clinical applications. <i>Nature Biotechnology</i> , <b>2016</b> , 34, 726-37	44.5	204
214	High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. <i>Prostate</i> , <b>2011</b> , 71, 281-8	4.2	179
213	Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. <i>Cell Reports</i> , <b>2014</b> , 8, 798-806	10.6	177
212	CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. <i>Cancer Research</i> , <b>2013</b> , 73, 2795-805	10.1	169
211	Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. <i>European Urology</i> , <b>2016</b> , 69, 592-598	10.2	167
210	Clinical significance of p53 alterations in surgically treated prostate cancers. <i>Modern Pathology</i> , <b>2008</b> , 21, 1371-8	9.8	165
209	Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients. <i>European Urology</i> , <b>2012</b> , 62, 333-40	10.2	162
208	Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. <i>Journal of Urology</i> , <b>2014</b> , 192, 409-14	2.5	153
207	Full functional-length urethral sphincter preservation during radical prostatectomy. <i>European Urology</i> , <b>2011</b> , 60, 320-9	10.2	138
206	Genomic Predictors of Outcome in Prostate Cancer. <i>European Urology</i> , <b>2015</b> , 68, 1033-44	10.2	136
205	Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 6579-84	12.9	128

204	Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. <i>Modern Pathology</i> , <b>2013</b> , 26, 975-83	9.8	121
203	TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF- $\beta$ -signaling. <i>BMC Cancer</i> , <b>2011</b> , 11, 507	4.8	117
202	Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1553-60	12.9	113
201	Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. <i>Journal of Pathology</i> , <b>2013</b> , 231, 130-41	9.4	112
200	Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. <i>BJU International</i> , <b>2006</b> , 98, 329-34	5.6	110
199	Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. <i>Cancer Discovery</i> , <b>2012</b> , 2, 1024-35	24.4	107
198	Current technique of open intrafascial nerve-sparing retropubic prostatectomy. <i>European Urology</i> , <b>2009</b> , 56, 317-24	10.2	102
197	Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. <i>Prostate</i> , <b>2009</b> , 69, 976-81	4.2	100
196	BAZZA (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. <i>Nature Genetics</i> , <b>2015</b> , 47, 22-30	36.3	99
195	Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 56-64	12.9	98
194	Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. <i>BJU International</i> , <b>2011</b> , 108, 1256-61	5.6	92
193	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. <i>Cancer Cell</i> , <b>2018</b> , 34, 996-1011.e8	24.3	89
192	Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. <i>Cancer</i> , <b>2008</b> , 113, 2068-72	6.4	88
191	Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical Prostatectomy. <i>European Urology</i> , <b>2016</b> , 69, 584-589	10.2	86
190	Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 1369-80	7.5	85
189	High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 1273-9	7.5	83
188	Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. <i>Scientific Reports</i> , <b>2016</b> , 6, 39736	4.9	73
187	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. <i>Cell Reports</i> , <b>2017</b> , 19, 2045-2059	10.6	72

186	Development and external validation of an extended repeat biopsy nomogram. <i>Journal of Urology</i> , <b>2007</b> , 177, 510-5	2.5	72
185	A feasible and time-efficient adaptation of NeuroSAFE for da Vinci robot-assisted radical prostatectomy. <i>European Urology</i> , <b>2014</b> , 66, 138-44	10.2	71
184	Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage. <i>Journal of Urology</i> , <b>2010</b> , 184, 1341-6	2.5	68
183	Mitochondrial mutations drive prostate cancer aggression. <i>Nature Communications</i> , <b>2017</b> , 8, 656	17.4	66
182	Human prostate cancer in a clinically relevant xenograft mouse model: identification of (1,6)-branched oligosaccharides as a marker of tumor progression. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1364-73	12.9	64
181	Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy Society Recommendation Consensus approach. <i>American Journal of Transplantation</i> , <b>2020</b> , 20, 1826-1836	8.7	62
180	Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. <i>BJU International</i> , <b>2010</b> , 106, 37-43	5.6	60
179	Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. <i>Modern Pathology</i> , <b>2014</b> , 27, 1612-20	9.8	59
178	TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. <i>Apmis</i> , <b>2009</b> , 117, 575-82	3.4	59
177	Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. <i>European Urology</i> , <b>2010</b> , 57, 562-8	10.2	58
176	Marked heterogeneity of ERG expression in large primary prostate cancers. <i>Modern Pathology</i> , <b>2013</b> , 26, 106-16	9.8	56
175	Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 7838-42	12.9	55
174	Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform. <i>PLoS ONE</i> , <b>2011</b> , 6, e16833	3.7	55
173	Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 235.e11-6	2.8	48
172	TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. <i>European Urology</i> , <b>2014</b> , 66, 978-81	10.2	48
171	β-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. <i>American Journal of Pathology</i> , <b>2014</b> , 184, 609-17	5.8	44
170	Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. <i>Neoplasia</i> , <b>2017</b> , 19, 707-715	6.4	43
169	External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. <i>Journal of Urology</i> , <b>2015</b> , 193, 1970-5	2.5	43

168	Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study. <i>European Urology Focus</i> , <b>2017</b> , 3, 646-649	5.1	42
167	Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. <i>European Urology</i> , <b>2017</b> , 71, 330-336	10.2	42
166	The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. <i>European Urology</i> , <b>2006</b> , 49, 273-8; discussion 278-9	10.2	41
165	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. <i>European Urology</i> , <b>2018</b> , 74, 376-386	10.2	40
164	High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. <i>Molecular Oncology</i> , <b>2013</b> , 7, 1001-11	7.9	40
163	High mitochondria content is associated with prostate cancer disease progression. <i>Molecular Cancer</i> , <b>2013</b> , 12, 145	42.1	39
162	Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. <i>Journal of Proteome Research</i> , <b>2012</b> , 11, 2452-66	5.6	38
161	Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance. <i>BJU International</i> , <b>2017</b> , 120, 808-814	5.6	37
160	Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. <i>Carcinogenesis</i> , <b>2015</b> , 36, 1333-40	4.6	37
159	Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3471-9	12.9	36
158	Molecular staging of prostate cancer in the year 2007. <i>World Journal of Urology</i> , <b>2007</b> , 25, 19-30	4	35
157	PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. <i>Oncotarget</i> , <b>2017</b> , 8, 65566-65576	3.3	35
156	SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. <i>Prostate</i> , <b>2013</b> , 73, 1690-8	4.2	34
155	High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 852-61	7.5	33
154	Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2354-63	7.5	33
153	Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 8377-87	3.3	33
152	Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria. <i>BJU International</i> , <b>2016</b> , 117, 55-61	5.6	32
151	Random forest-based modelling to detect biomarkers for prostate cancer progression. <i>Clinical Epigenetics</i> , <b>2019</b> , 11, 148	7.7	32

150	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. <i>European Urology</i> , <b>2018</b> , 73, 674-683	10.2	32
149	Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy. <i>Journal of Urology</i> , <b>2015</b> , 193, 479-83	2.5	32
148	Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. <i>International Journal of Cancer</i> , <b>2013</b> , 132, 1333-40	7.5	32
147	Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. <i>Modern Pathology</i> , <b>2013</b> , 26, 733-42	9.8	32
146	Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. <i>European Urology</i> , <b>2009</b> , 55, 394-401	10.2	31
145	Deletion of 8p is an independent prognostic parameter in prostate cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 379-392	3.3	30
144	A Novel Gene Signature-Based Model Predicts Biochemical Recurrence-Free Survival in Prostate Cancer Patients after Radical Prostatectomy. <i>Cancers</i> , <b>2019</b> , 12,	6.6	30
143	Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer. <i>Carcinogenesis</i> , <b>2017</b> , 38, 19-27	4.6	29
142	Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 329.e13-9	2.8	29
141	The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 1399-407	7.5	29
140	Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 27966-79	3.3	28
139	Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN Guideline. <i>Journal of Urology</i> , <b>2017</b> , 198, 354-361	2.5	27
138	The prognostic value of SUMO1/Sentrin specific peptidase 1 (SEN1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. <i>BMC Cancer</i> , <b>2015</b> , 15, 538	4.8	27
137	MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype. <i>Anticancer Research</i> , <b>2014</b> , 34, 2255-61	2.3	27
136	HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. <i>Oncotarget</i> , <b>2015</b> , 6, 12822-34	3.3	26
135	Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy. <i>BJU International</i> , <b>2017</b> , 119, 717-723	5.6	25
134	Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. <i>Journal of Clinical Pathology</i> , <b>2013</b> , 66, 563-8	3.9	25
133	Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers. <i>Journal of Proteomics</i> , <b>2015</b> , 119, 218-29	3.9	24

132	Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128525	3.7	24
131	High nuclear karyopherin $\beta$ expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. <i>Modern Pathology</i> , <b>2014</b> , 27, 96-106	9.8	24
130	Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 2056	4.9	23
129	Aberrant presentation of HPA-reactive carbohydrates implies Selectin-independent metastasis formation in human prostate cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1791-802	12.9	23
128	Deletion of 18q is a strong and independent prognostic feature in prostate cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 86339-86349	3.3	23
127	Incidence, Risk Factors, Management, and Complications of Rectal Injuries During Radical Prostatectomy. <i>European Urology Focus</i> , <b>2018</b> , 4, 554-557	5.1	22
126	13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. <i>Genes Chromosomes and Cancer</i> , <b>2018</b> , 57, 504-512	5	22
125	Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR. <i>International Journal of Oncology</i> , <b>2014</b> , 44, 609-15	4.4	22
124	Response to olaparib in a germline mutated prostate cancer and genetic events associated with resistance. <i>Journal of Physical Education and Sports Management</i> , <b>2019</b> , 5,	2.8	21
123	Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 1199-206	7.5	21
122	A visual-interactive system for prostate cancer cohort analysis. <i>IEEE Computer Graphics and Applications</i> , <b>2015</b> , 35, 44-55	1.7	21
121	The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. <i>International Journal of Oncology</i> , <b>2012</b> , 40, 261-8	4.4	21
120	Molecular cancer phenotype in normal prostate tissue. <i>European Urology</i> , <b>2009</b> , 55, 885-90	10.2	21
119	Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 108923-108935	3.3	21
118	HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. <i>Experimental and Molecular Pathology</i> , <b>2015</b> , 98, 419-26	4.4	20
117	Immunohistochemically detected IDH1 mutation is rare and mostly heterogeneous in prostate cancer. <i>World Journal of Urology</i> , <b>2018</b> , 36, 877-882	4	20
116	Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients. <i>BMC Cancer</i> , <b>2016</b> , 16, 641	4.8	19
115	PSMA expression is highly homogenous in primary prostate cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2015</b> , 23, 449-55	1.9	19

114	Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection. <i>Prostate</i> , <b>2015</b> , 75, 1484-91	4.2	19
113	Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level <i>European Urology</i> , <b>2008</b> , 53, 750-7	10.2	19
112	Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. <i>Oncology Letters</i> , <b>2013</b> , 6, 1245-1252	2.6	18
111	Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. <i>Prostate</i> , <b>2016</b> , 76, 259-72	4.2	18
110	Tumor volume in insignificant prostate cancer: increasing threshold gains increasing risk. <i>Prostate</i> , <b>2015</b> , 75, 45-9	4.2	17
109	Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence. <i>Human Pathology</i> , <b>2013</b> , 44, 1789-96	3.7	17
108	Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. <i>Urology</i> , <b>2009</b> , 74, 1169-73	1.6	17
107	p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. <i>Tumor Biology</i> , <b>2016</b> , 37, 12655-12663	2.9	16
106	The presence of prostate cancer on saturation biopsy can be accurately predicted. <i>BJU International</i> , <b>2010</b> , 105, 636-41	5.6	16
105	Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 102-107	6.2	16
104	High-Level Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	15
103	Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse. <i>PLoS ONE</i> , <b>2014</b> , 9, e100469	3.7	15
102	Evolution of Targeted Prostate Biopsy by Adding Micro-Ultrasound to the Magnetic Resonance Imaging Pathway. <i>European Urology Focus</i> , <b>2021</b> , 7, 1292-1299	5.1	15
101	High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 37	4.8	14
100	Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment. <i>European Urology</i> , <b>2016</b> , 70, 824-828	10.2	14
99	Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer. <i>Scientific Reports</i> , <b>2018</b> , 8, 17535	4.9	14
98	Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. <i>BMC Cancer</i> , <b>2019</b> , 19, 193	4.8	13
97	Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence. <i>Prostate</i> , <b>2018</b> , 78, 676-681	4.2	13



96	Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence. <i>Human Pathology</i> , <b>2016</b> , 48, 102-10	3.7	13
95	Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. <i>Experimental and Molecular Pathology</i> , <b>2013</b> , 95, 227-34	4.4	13
94	The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2802-11	12.9	13
93	Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer. <i>Clinical Chemistry</i> , <b>2020</b> , 66, 161-168	5.5	13
92	Apurinic/aprimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion. <i>Molecular Carcinogenesis</i> , <b>2017</b> , 56, 2135-2145	5	12
91	PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 612	4.8	12
90	High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. <i>Experimental and Therapeutic Medicine</i> , <b>2013</b> , 5, 102-106	2.1	12
89	Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. <i>Oncotarget</i> , <b>2019</b> , 10, 5439-5453	3.3	12
88	Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. <i>Neoplasia</i> , <b>2017</b> , 19, 279-287	6.4	11
87	Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients. <i>BJU International</i> , <b>2012</b> , 110, 1714-20	5.6	11
86	A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 1685-1696	7.5	11
85	Upregulation of centromere protein F is linked to aggressive prostate cancers. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 5491-5504	3.6	11
84	FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy. <i>Carcinogenesis</i> , <b>2017</b> , 38, 1180-1187	4.6	10
83	βII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. <i>World Journal of Urology</i> , <b>2015</b> , 33, 1561-9	4	10
82	CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate. <i>BioMed Research International</i> , <b>2014</b> , 2014, 356427	3	10
81	Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancer. <i>Urology</i> , <b>2008</b> , 72, 1208-11; discussion 1212-3	1.6	10
80	Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	9
79	NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer. <i>Prostate</i> , <b>2014</b> , 74, 1012-22	9	9

78	Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer. <i>International Journal of Oncology</i> , <b>2015</b> , 46, 1637-42	4.4	9
77	Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2018</b> , 21, 386-393	6.2	8
76	High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer. <i>PLoS ONE</i> , <b>2015</b> , 10, e0134614	3.7	8
75	From gene to clinic: TMA-based clinical validation of molecular markers in prostate cancer. <i>Methods in Molecular Biology</i> , <b>2010</b> , 664, 177-89	1.4	8
74	Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer. <i>Molecular Oncology</i> , <b>2020</b> , 14, 129-138	7.9	8
73	High B7-H3 expression is linked to increased risk of prostate cancer progression. <i>Pathology International</i> , <b>2020</b> , 70, 733-742	1.8	8
72	A Clinician@ Guide to Avoiding and Managing Common Complications During and After Robot-assisted Laparoscopic Radical Prostatectomy. <i>European Urology Focus</i> , <b>2016</b> , 2, 30-48	5.1	8
71	Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers. <i>Human Pathology</i> , <b>2015</b> , 46, 514-23	3.7	7
70	The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients. <i>Psycho-Oncology</i> , <b>2020</b> , 29, 1338-1346	3.9	7
69	Analysis of the Effects of Day-Time vs. Night-Time Surgery on Renal Transplant Patient Outcomes. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	7
68	Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer. <i>Aging</i> , <b>2019</b> , 11, 7859-7879	5.6	7
67	High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer. <i>Prostate</i> , <b>2017</b> , 77, 1528-1538	4.2	6
66	Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. <i>Oncology Reports</i> , <b>2015</b> , 34, 1211-20	3.5	6
65	Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 3897-904	3.3	6
64	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. <i>World Journal of Urology</i> , <b>2020</b> , 38, 2185-2196	4	6
63	Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers. <i>Scientific Reports</i> , <b>2020</b> , 10, 8916	4.9	5
62	Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer. <i>Prostate</i> , <b>2020</b> , 80, 1097-1107	4.2	5
61	Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. <i>BMC Cancer</i> , <b>2017</b> , 17, 504	4.8	5

60	Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. <i>European Urology Focus</i> , <b>2018</b> , 4, 376-384	5.1	5
59	The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. <i>Prostate Cancer</i> , <b>2018</b> , 2018, 5821616	1.9	5
58	Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer. <i>Experimental and Molecular Pathology</i> , <b>2018</b> , 105, 50-56	4.4	5
57	Native Nephrectomy before and after Renal Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	4
56	Oncological outcome after radical prostatectomy: Marital status does not make a difference. <i>International Journal of Urology</i> , <b>2015</b> , 22, 484-9	2.3	4
55	Comparison between complication rates of laser prostatectomy electrocautery transurethral resection of the prostate: A population-based study. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, E419-24	1.2	4
54	Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients. <i>Cancer Medicine</i> , <b>2020</b> , 9, 1409-1418	4.8	4
53	High RSF1 protein expression is an independent prognostic feature in prostate cancer. <i>Acta Oncologica</i> , <b>2020</b> , 59, 268-273	3.2	4
52	Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions. <i>Pathology and Oncology Research</i> , <b>2020</b> , 26, 2709-2722	2.6	4
51	Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 137, 93-107	7.5	4
50	EGFR as a stable marker of prostate cancer dissemination to bones. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 1767-1774	8.7	4
49	Re: The Molecular Taxonomy of Primary Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 69, 1157	10.2	4
48	Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. <i>Pathology International</i> , <b>2020</b> , 70, 441-451	1.8	4
47	VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 8591-606	6.3	3
46	A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 604-609	8.7	3
45	Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer. <i>Scientific Reports</i> , <b>2020</b> , 10, 3250	4.9	3
44	Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 31494-31508	3.3	3
43	Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy. <i>Oncotarget</i> , <b>2019</b> , 10, 4973-4986	3.3	3

42	Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion. <i>Oncotarget</i> , <b>2019</b> , 10, 7096-7111	3.3	3
41	Upregulation of SPDEF is associated with poor prognosis in prostate cancer. <i>Oncology Letters</i> , <b>2019</b> , 18, 5107-5118	2.6	3
40	Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. <i>BioMed Research International</i> , <b>2020</b> , 2020, 5845374	3	3
39	Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer. <i>BMC Cancer</i> , <b>2020</b> , 20, 1220	4.8	3
38	5q21 deletion is often heterogeneous in prostate cancer. <i>Genes Chromosomes and Cancer</i> , <b>2019</b> , 58, 509-515		3
37	High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases. <i>Oncology Letters</i> , <b>2018</b> , 16, 6238-6244	2.6	3
36	Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, 296-304.e3	3.3	3
35	High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens. <i>BJU International</i> , <b>2017</b> , 120, 365-376	5.6	2
34	SNW1 is a prognostic biomarker in prostate cancer. <i>Diagnostic Pathology</i> , <b>2019</b> , 14, 33	3	2
33	Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 575.e1-575.e7	2.8	2
32	Safe-R: a novel score, accounting for oncological safe nerve-sparing at radical prostatectomy for localized prostate cancer. <i>World Journal of Urology</i> , <b>2015</b> , 33, 77-83	4	2
31	Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer. <i>Disease Markers</i> , <b>2020</b> , 2020, 7050146	3.2	2
30	Robot-Assisted versus Laparoscopic Donor Nephrectomy: A Comparison of 250 Cases. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
29	Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. <i>Molecular Medicine</i> , <b>2020</b> , 26, 24	6.2	2
28	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 575-583	7.5	2
27	High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer. <i>Pathology</i> , <b>2020</b> , 52, 421-430	1.6	2
26	Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. <i>Neoplasia</i> , <b>2019</b> , 21, 872-881	6.4	2
25	Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer. <i>Microarrays (Basel, Switzerland)</i> , <b>2014</b> , 3, 137-58		2

24	Value of cell cycle progression (CCP) score to predict biochemical recurrence and definitive post-surgical pathology.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5043-5043	2.2	2
23	Predicting radical prostatectomy outcome: Cell cycle progression (CCP) score compared with primary Gleason grade among men with clinical Gleason less than 7 who are upgraded to Gleason 7.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 13-13	2.2	2
22	A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer. <i>Oncotarget</i> , <b>2019</b> , 10, 1729-1744	3.3	2
21	Repeat Radiation for Local Recurrence of Head and Neck Tumors and in Prostate Cancer. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , <b>2020</b> , 117, 167-174	2.5	2
20	Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. <i>Prostate</i> , <b>2019</b> , 79, 302-311	4.2	2
19	Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 748-758	7.5	2
18	Deletion of 3p13 is a late event linked to progression of : fusion prostate cancer. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 5909-5917	3.6	2
17	Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of deleted prostate cancers. <i>Cancer Biology and Medicine</i> , <b>2019</b> , 16, 319-330	5.2	1
16	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 477, 625-636	5.1	1
15	Should We Perform Old-for-Old Kidney Transplantation during the COVID-19 Pandemic? The Risk for Post-Operative Intensive Stay. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	1
14	Random forest-based modelling to detect biomarkers for prostate cancer progression		1
13	Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. <i>Cancer Biology and Medicine</i> , <b>2021</b> , 18, 245-255	5.2	1
12	High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer. <i>BMC Cancer</i> , <b>2019</b> , 19, 944	4.8	0
11	Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2021</b> , 29, e29-e38	1.9	0
10	Active Surveillance und die moderne Diagnostik des Prostatakarzinoms. <i>Onkologe</i> , <b>2019</b> , 25, 304-314	0.1	
9	Radikale Prostatektomie beim lokal fortgeschrittenen und metastasierten Prostatakarzinom. <i>Onkologe</i> , <b>2019</b> , 25, 315-321	0.1	
8	Aktive Berwachung des Prostatakarzinoms. <i>Uro-News</i> , <b>2019</b> , 23, 46-50	0	
7	Prostatakarzinom: Onkologische Kennzeichen. <i>Springer Reference Medizin</i> , <b>2020</b> , 1-18	0	

- 6 Therapie bei isoliertem PSA-Anstieg. *Springer Reference Medizin*, **2020**, 1-12 0
- 5 Toxicity in a multimodality approach of radical prostatectomy with radiation and hormonal therapy.. *Journal of Clinical Oncology*, **2016**, 34, 107-107 2.2
- 4 Association of nuclear accumulation of p53 with ERG fusion and poor prognosis in prostate cancer.. *Journal of Clinical Oncology*, **2012**, 30, 124-124 2.2
- 3 Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy.. *Journal of Clinical Oncology*, **2014**, 32, 17-17 2.2
- 2 Aktive Berwachung des Prostatakarzinoms. *Im Focus Onkologie*, **2019**, 22, 54-58 0
- 1 The gordian knots. *World Journal of Urology*, **2020**, 38, 1815-1817 4